Pokorná V, Jurkovicová O, Kaluzay J, Stecová A, Pont'uch P
IV Interná kIinika Lekárskej fakulty UKa FNsP Bratislava, Slovenská republika.
Vnitr Lek. 2010 Aug;56(8):788-94.
NT-proBNP, a well-established diagnostic and prognostic marker in clinical practice, is significantly elevated in individuals with atrial fibrillation (AF), even in absence of heart failure or major structural heart disease.
The aim of this study was to determine the cut-off value of NT-proBNP for diagnosis of heart failure in individuals with atrial fibrillation.
We compared 44 patients (25 male/19 female) with AF and concomitant overt heart failure [age 76 (62-82) years; median (interquartile range - IQR)] versus 29 patients (16 male/13 female) with AF with no signs of heart failure [age 59 (50-67) years; median (IQR)]. We considered the underlying causes of heart failure and its severity, comorbidities, echocardiographic and selected laboratory parameters, the body mass index as well as the treatment at discharge. We determined the cut-off value for heart failure and major structural heart disease using ROC curve analysis.
Median NT-proBNP in the group of patients with AF and concomitant heart failure was 3 218 ng/l (IQR 1 758-7 480 ng/l) vs 981 ng/l (IQR 431-1 685 ng/l) in the group of patients with AF with no signs of heart failure; this difference was statistically significant (p < 0.001). The level of NT-proBNP higher than 1 524 ng/l in patients with AF was diagnostic of major structural heart disease and pointed towards a possible heart failure (sensitivity 80%, specificity of 76%, accuracy 78%, positive predictive value 83%, negative predictive value 71%). The NT-proBNP levels significantly correlated with age (p < 0.001), left atrial diameter (p < 0.01) and furosemide dose at discharge (p < 0.05). The NT-proBNP levels significantly negatively correlated with left ventricular ejection fraction (p < 0.001) and body mass index (p < 0.05).
We found out that NT-proBNP is significantly elevated in patients with AF with preserved left ventricular function and in absence of heart failure and significantly correlates with age, left ventricular ejection fraction, left atrial diameter, body mass index and the furosemide dose necessary to achieve cardiac compensation. Furthermore, we determined the NT-proBNP cut-offvalue predictive of a possible heart failure in patients with AF.
N末端B型利钠肽原(NT-proBNP)是临床实践中一种成熟的诊断和预后标志物,在房颤(AF)患者中显著升高,即使在没有心力衰竭或严重结构性心脏病的情况下也是如此。
本研究的目的是确定NT-proBNP在房颤患者中诊断心力衰竭的临界值。
我们比较了44例合并明显心力衰竭的房颤患者(25例男性/19例女性)[年龄76(62 - 82)岁;中位数(四分位间距 - IQR)]与29例无心力衰竭体征的房颤患者(16例男性/13例女性)[年龄59(50 - 67)岁;中位数(IQR)]。我们考虑了心力衰竭的潜在病因及其严重程度、合并症、超声心动图和选定的实验室参数、体重指数以及出院时的治疗情况。我们使用受试者工作特征(ROC)曲线分析确定心力衰竭和严重结构性心脏病的临界值。
合并心力衰竭的房颤患者组中NT-proBNP的中位数为3218 ng/l(IQR 1758 - 7480 ng/l),而无心力衰竭体征的房颤患者组中为981 ng/l(IQR 431 - 1685 ng/l);这种差异具有统计学意义(p < 0.001)。房颤患者中NT-proBNP水平高于1524 ng/l可诊断为严重结构性心脏病,并提示可能存在心力衰竭(敏感性80%,特异性76%,准确性78%,阳性预测值83%,阴性预测值71%)。NT-proBNP水平与年龄(p < 0.001)、左心房直径(p < 0.01)和出院时呋塞米剂量(p < 0.05)显著相关。NT-proBNP水平与左心室射血分数(p < 0.001)和体重指数(p < 0.05)显著负相关。
我们发现,在左心室功能保留且无心力衰竭的房颤患者中NT-proBNP显著升高,并且与年龄、左心室射血分数、左心房直径、体重指数以及实现心脏代偿所需的呋塞米剂量显著相关。此外,我们确定了房颤患者中预测可能发生心力衰竭的NT-proBNP临界值。